Hemophilia therapy innovation: Development of an advanced category recombinant factor VIII by a plasma/albumin-free method - Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK

被引：16

作者：

Ewenstein, BM

Collins, P

Tarantino, MD

Negrier, C

Blanchette, V

Shapiro, AD

Baker, D

Spotts, G

Sensel, M

Yi, SE

Gomperts, ED

机构：

[1] Baxter Healthcare Corp, Baxter Biosci, Westlake Village, CA 91362 USA

[2] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales

[3] Comprehens Bleeding Disorders Ctr, Peoria, IL USA

[4] Hop Edouard Herriot, Lyon, France

[5] Hosp Sick Children, Toronto, ON M5G 1X8, Canada

[6] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA

来源：

SEMINARS IN HEMATOLOGY | 2004年 / 41卷 / 01期

关键词：

D O I：

10.1053/j.seminhetnatol.2004.01.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1 / 18

页数：18

共 53 条

[31] RAPID ISOLATION OF HIGHLY PRODUCTIVE RECOMBINANT CHINESE-HAMSTER OVARY CELL-LINES [J].

MILOUX, B ;

LUPKER, JH .

GENE, 1994, 149 (02) :341-344

[32] EFFICIENT CONSTITUTIVE PRODUCTION OF HUMAN IFN-GAMMA IN CHINESE-HAMSTER OVARY CELLS [J].

MORY, Y ;

BENBARAK, J ;

SEGEV, D ;

COHEN, B ;

NOVICK, D ;

FISCHER, DG ;

RUBINSTEIN, M ;

KARGMAN, S ;

ZILBERSTEIN, A ;

VIGNERON, M ;

REVEL, M .

DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1986, 5 (03) :181-193

[33] Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII [J].

Moussalli, M ;

Pipe, SW ;

Hauri, HP ;

Nichols, WC ;

Ginsburg, D ;

Kaufman, RJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (46) :32539-32542

[34] Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII [J].

Nichols, WC ;

Seligsohn, U ;

Zivelin, A ;

Terry, VH ;

Hertel, CE ;

Wheatley, MA ;

Moussalli, MJ ;

Hauri, HP ;

Ciavarella, N ;

Kaufman, RJ ;

Ginsburg, D .

CELL, 1998, 93 (01) :61-70

[35] Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa [J].

Pipe, SW ;

Kaufman, RJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) :11851-11856

[36] Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin [J].

Pipe, SW ;

Morris, JA ;

Shah, J ;

Kaufman, RJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8537-8544

[37]

Ricketts MN, 1997, CAN MED ASSOC J, V157, P1367

[38] European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients [J].

Rothschild, C ;

Scharrer, I ;

Brackmann, HH ;

Stieltjes, N ;

Vicariot, M ;

Torchet, MF ;

Effenberger, W .

HAEMOPHILIA, 2002, 8 :10-14

[39] The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor [J].

Saenko, EL ;

Scandella, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (29) :18007-18014

[40] The future of recombinant coagulation factors [J].

Saenko, EL ;

Ananyeva, NM ;

Shima, M ;

Hauser, CAE ;

Pipe, SW .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :922-930

← 1 2 3 4 5 6 →